

Review

Not peer-reviewed version

Chemokine CX3CL1 (Fractalkine) Signaling and Diabetic Encephalopathy

[Mateusz Wątroba](#), [Anna D Grabowska](#), [Dariusz Szukiewicz](#) *

Posted Date: 3 June 2024

doi: 10.20944/preprints202406.0020.v1

Keywords: diabetic encephalopathy; chemokine CX3CL1; fractalkine; central nervous system; neuroinflammation; diabetes mellitus; hyperglycemia; advanced glycation end products; CX3CL1/CX3CR1 axis



Preprints.org is a free multidiscipline platform providing preprint service that is dedicated to making early versions of research outputs permanently available and citable. Preprints posted at Preprints.org appear in Web of Science, Crossref, Google Scholar, Scilit, Europe PMC.

Copyright: This is an open access article distributed under the Creative Commons Attribution License which permits unrestricted use, distribution, and reproduction in any medium, provided the original work is properly cited.

Review

Chemokine CX3CL1 (Fractalkine) Signaling and Diabetic Encephalopathy

Mateusz Wątroba, Anna D Grabowska and Dariusz Szukiewicz *

Laboratory of the Blood-Brain Barrier, Department of Biophysics, Physiology & Pathophysiology, Medical University of Warsaw; Chałubińskiego 5, 02-400 Warsaw, Poland; mateusz.watroba@wum.edu.pl; anna.sepulveda@wum.edu.pl; dariusz.szukiewicz@wum.edu.pl

* Correspondence: dariusz.szukiewicz@wum.edu.pl

Abstract: Diabetes mellitus (DM) is the most common metabolic disease in humans, and its prevalence is increasing worldwide in parallel with the obesity pandemic. A lack of insulin or insulin resistance, and consequently hyperglycemia, leads to many systemic disorders, among which diabetic encephalopathy (DE) is a long-term complication of the central nervous system (CNS), characterized by cognitive impairment and motor dysfunctions. The role of oxidative stress and neuroinflammation in the pathomechanism of DE has been proven. Fractalkine (CX3CL1) has unique properties as an adhesion molecule and chemoattractant, and by acting on its only receptor, CX3CR1, it regulates the activity of microglia in physiological states and neuroinflammation. Depending on the clinical context, CX3CL1-CX3CR1 signaling may have neuroprotective effects by inhibiting the inflammatory process in microglia or, conversely, maintaining/intensifying inflammation and neurotoxicity. This review discusses the evidence supporting that the CX3CL1-CX3CR1 pair is neuroprotective and other evidence that it is neurotoxic. Interrupting the vicious cycle within neuron-microglia interactions may be a therapeutic goal in DE by limiting the inflammatory response.

Keywords: diabetic encephalopathy; chemokine CX3CL1; fractalkine; central nervous system; neuroinflammation; diabetes mellitus; hyperglycemia; advanced glycation end products; CX3CL1/CX3CR1 axis

1. Introductory Overview – Diabetes as a Risk Factor for Encephalopathy

Diabetes mellitus (DM) is a heterogeneous, chronic metabolic disease characterized by elevated blood glucose levels. Hyperglycemia in DM is a consequence of defects in insulin secretion, tissue resistance to insulin or a combination of both of these factors [1]. Over time, individuals with glucose metabolism disorders, especially poorly controlled diabetes, are predisposed to serious complications, including cardiovascular disease, kidney disease, blindness, neuropathy, lower-extremity amputation, and diabetic encephalopathy (DE), which is the subject of this review [2,3]. DE is a chronic complication of DM that affects the central nervous system (CNS) and is characterized by cognitive impairment and motor dysfunctions [4]. Therefore, patients with DE are at greater risk of both dementia and postural perturbations (e.g., balance disorders) [5,6]. Moreover, considering the prevalence of diabetes, mainly type 2 diabetes, which is largely influenced by the obesity pandemic, DE has become a common CNS complication of DM, with no effective therapies currently available [7–9]. Recent studies have indicated that damage to synaptic mitochondria may play an important role in the pathomechanism of DE, but the nature of this phenomenon remains unclear [10].

1.1. Consequences of the Lack of or Insufficient Action of Insulin

The central actions of insulin appear to support cognitive functions by regulating neurotransmitter release, synaptic transmission, and neuronal glucose uptake [11–13]. Disturbed brain glucose metabolism and hippocampal insulin resistance may impair cognitive functions and contribute to neurodegeneration [14,15]. In addition, deficiency of central insulin may reduce cerebral

blood flow and blood supply to the cerebral cortex, which can also result in cognitive impairment [16]. Moreover, such deficiency of insulin, resulting either from absolute insulin deficiency or from brain insulin resistance, may promote the accumulation of A β aggregates and hyperphosphorylation of tau proteins because the physiological effects of insulin can oppose these processes [17–21]. Advanced glycation end products (AGEs) can stimulate receptors for advanced glycation end products (RAGE) and Toll-like receptor 4 (TLR4), which may result in neuroinflammation, stimulation of nuclear factor kappa-light-chain-enhancer of activated B cells (NF- κ B)-dependent signaling pathways and the release of proinflammatory cytokines [22–27]. Therefore, neuroinflammation is a constant component of the pathophysiology of DE [28,29].

1.2. The damaging Effects of Chronic Hyperglycemia

Moreover, chronic hyperglycemia may damage the blood–brain barrier, mainly through its pro-oxidative effects [24,30]. All these effects cause diabetes, a pathological condition associated with insulin deficiency, to promote neurodegeneration and the occurrence of cognitive deficits, recapitulating to some extent the same pathomechanisms that underlie other neurodegenerative diseases, such as Alzheimer's disease [31–36]. This may justify the introduction of DE, defined as the sum of the effects of insufficient insulin on the CNS. The pathomechanisms of cognitive deficits occurring in DE largely overlap with the pathomechanisms of other neurodegenerative diseases, resulting in neuronal loss [37]. The duration of diabetes increases the incidence of both diabetic neuropathy and DE, which do not immediately appear at the onset of the disease, especially when patients' blood glucose levels are well stabilized [38]. In patients with diabetes diagnosed less than 12 months prior, the incidence of diabetic neuropathy equals approximately 10%, increasing to 50% 25 years after diagnosis [39]. The most common symptoms of diabetic peripheral neuropathy include paresthesia, numbness, and a burning sensation [40].

2. Chemokine CX3CL1 (Fractalkine)

2.1. Structure

C-X3-C motif chemokine ligand 1 (CX3CL1), also known as fractalkine or neurotactin, is the only member of the δ subfamily of chemokines and seems to bind to only one receptor, CX3CR1, a transmembrane G α i protein-coupled receptor [41]. Many other substances belonging to the chemokine family show less specific binding activity than CX3CL1 [55]. The full-length CX3CL1 molecule is larger than most other chemokines [42] and has two forms. The 95-kDa full-length membrane-bound molecule contains a 76-amino-acid N-terminal chemokine domain, a 241-amino-acid mucin-like glycosylated stalk, a 19-amino-acid hydrophobic transmembrane region (α helix), and a 37-amino-acid intracellular C-terminal domain [42,43]. Another form is a soluble molecule of approximately 70 kDa that contains an N-terminal chemokine domain and an extracellular mucin-like stalk [42,43]. The soluble domain of CX3CL1 acts as a signaling molecule (chemoattractant) and can bind to CX3CR1 receptors expressed on microglia [44]. In contrast, its transmembrane mucin-like stalk may act as an adhesion molecule for microglia and infiltrate leukocytes during the inflammatory response [45,46]. The molecular structures of both forms of FKN are shown in Figure 1.




Figure 1. Schematic structure of the C-X-C motif chemokine ligand 1 (CX3CL1), also known as fractalkine or neurotactin. Both forms of the chemokine are shown: membrane-bound (transmembrane) CX3CL1 and soluble CX3CL1. The soluble CX3CL1, containing an N-terminal chemokine domain and an extracellular mucin-like stalk, is generated by cleavage of the membrane-bound molecule near the outer surface of the membrane (marked symbolically with scissors and crossed red lines). Release of soluble CX3CL1 may occur upon exposure to a disintegrin and metalloproteinase domain-containing protein 10 (ADAM10), tumor necrosis factor alpha (TNF- α) converting enzyme (TACE or ADAM17), matrix metalloproteinase-2 (MMP-2) or cathepsins (CTS). Adapted from [47].

2.2. CX3CL1 in the CNS

In the CNS, CX3CL1 is constitutively expressed in neurons, especially in hippocampal neurons [48], while in astrocytes, its expression can be induced by TNF- α and interferon gamma (IFN- γ) [49]. CX3CR1 receptor activation is associated with several intracellular second messengers. In the brain, CX3CR1 expression is limited to microglia [48].

Activation of the CX3CL1-CX3CR1 signaling pathway in microglia, both by the soluble form of CX3CL1 and by its membrane-bound form, inhibits lipopolysaccharide (LPS)-induced major histocompatibility complex class II (MHC2) and cluster of differentiation 40 (CD40) mRNA biosynthesis and the level of interleukin-1 beta (IL-1 β) expression, and these anti-inflammatory effects depend on the activation of protein kinase B (Akt) and phosphoinositide 3-kinase (PI3K) [50].

Activation of the CX3CL1-CX3CR1 axis also stimulates Akt activation in microglia in a dose- and time-dependent manner. Treatment of primary cocultures of glial cells and neurons with fractalkine results in transient phosphorylation of Akt within 10 minutes and extracellular signal-regulated kinase 1/2 (ERK1/2) within 1 minute of exposure to CX3CL1 [51]. Moreover, CX3CL1 significantly inhibits neuronal calcium influx induced by N-methyl-D-aspartate (NMDA) receptor activation, and this effect can be abrogated by inhibition of the ERK1/2-dependent signaling pathway. CX3CL1 also inhibits NMDA-dependent apoptosis through Akt- and ERK1/2-dependent signaling pathways [51]. This effect is likely mediated by the activation of microglia rather than by a direct effect of CX3CL1 on neurons. Treatment of hippocampal neuron cultures with the soluble form of CX3CL1 activates cyclic adenosine monophosphate (cAMP)/Ca²⁺ response element binding protein (CREB), a transcription factor, and ERK1/2 kinase but not kinases such as cjun NH(2)-terminal kinase (JNK) or mitogen-activated protein kinases P38 (P38 MAPK) [52].

In addition, it induces the translocation of the NF- κ B p65 subunit to the cell nucleus. A specific PI3K inhibitor abrogated the translocation of the NF- κ B p65 subunit to the cell nucleus, suggesting that CX3CL1-CX3CR1-dependent signaling activates NF- κ B via Akt [53]. These results, however, have not been confirmed in other experimental models and could have been due the specific cell culture system used, e.g., contamination of the culture with microglia.

By acting on the CX3CR1 receptor, CX3CL1 modulates α -amino-3-hydroxy-5-methyl-4-isoxazolepropionic acid (AMPA) receptor phosphorylation, increasing calcium influx and inhibiting excitatory postsynaptic potentials and long-term potentiation (LTP) [54].

CX3CL1 may also enhance inhibitory postsynaptic currents, possibly by increasing neuronal responsiveness to γ -aminobutyric acid (GABA) and GABA-dependent chloride anion influx into cells [55]. CX3CL1 can activate the CX3CR1 receptor on microglia with the subsequent release of adenosine, which may, in turn, activate adenosine (A)₃ (R) receptors on neurons, inducing a signaling cascade that results in the modulation of GABA-A receptors, increasing their sensitivity to GABA [56]. Adenosine may also activate adenosine A₂AR receptors on microglia, inducing the release of D-serine, which acts as a coagonist of the NMDA receptor, increasing calcium influx into cells through NMDA receptor activation [57]. Microglia-derived adenosine may also exert a neuroprotective effect by activating the A₁R adenosine receptor in neurons [58].

Several studies have shown that CX3CL1 inhibits LPS-induced microglial activation by reducing the production of nitric oxide (NO), interleukin-6 (IL-6) and TNF- α [50,59] and inhibits the neurotoxic effects of LPS-activated microglia in vitro by limiting the release of proinflammatory mediators [59]. These data suggest that high levels of endogenous CX3CL1 expressed in adult CNS neurons lead to tonic activation of CX3CR1 on microglia and act as a neuronal signal maintaining microglia in a quiescent state [60,61], thus contributing to the neuroprotective role of CX3CL1-CX3CR1-dependent signaling. In contrast, in mixed cultures of neuronal and glial cells collected from CX3CR1^{-/-} mice, as well as in microglial murine BV-2 cells with silenced CX3CR1 production, the LPS-induced release of TNF- α , NO and superoxide molecules is reduced in comparison to cells from wild-type (WT) mice [62], suggesting that CX3CL1 is also involved in the release of proinflammatory mediators from activated microglia.

3. Physiological Role of the CX3CL1-CX3CR1 Signaling Pathway in the CNS

3.1. Main CX3CL1-CX3CR1 Signaling Pathways

The attachment of the CX3CL1 molecule to the extracellular determinants of CX3CR1 causes conformational rearrangements preceding the activation of heterotrimeric G proteins (the G $\alpha\beta\gamma$ heterotrimer) of the G protein complex associated with CX3CR1 [63–65]. The G α subunit interacts with G protein regulatory (GPR) domain-containing proteins and synembryn (RIC8), a nonreceptor guanine-nucleotide exchange factor for G α subunits, to exchange the guanosine-5'-triphosphate (GTP) molecule for guanosine-5'-diphosphate (GDP) [66,67]. The presence of active GTP-bound G α in the G protein complex leads to its dissociation into G α i-GTP and a G $\beta\gamma$ dimer. Activated G α i interacts with downstream effectors [68].

The emerging CX3CL1-CX3CR1 signaling axis utilizes several well-described pathways to activate numerous transcription factors, such as signal transducer and activator of transcription protein (STAT), NF- κ B and CREB, while inhibiting other factors (e.g., members of the class O forkhead box transcription factor [FOXO]) [69–71].

Most CX3CR1-related signaling pathways have been shown to involve other chemokine receptors. These include, among others:

1. stimulating the mobilization of calcium ions from intracellular resources through the phospholipase C (PLC)/protein kinase C (PKC) pathway [72,73];
2. activation of appropriate kinases with subsequent downstream signaling within
 - a.) the Janus kinase (JAK)/STAT pathway
 - b.) phosphoinositide 3-kinase (PI3K)/protein kinase B (Akt)/I κ B pathway
 - c.) Ras kinases (Ras)/Raf kinases (Raf)/mitogen-activated protein kinase kinase

- (MEK)/extracellular signal-regulated kinase (ERK)
- d.) MEK kinase (MEKK)/cJun NH(2)-terminal kinase (JNK)/CREB or MEKK/mitogen-activated protein kinase (P38)/CREB pathways [50,74–76].
- The above signaling pathways are shown in Figure 2.




Figure 2. Downstream signaling pathways (A., B., C., D.) after activation of the CX3C motif chemokine receptor 1 (CX3CR1) caused by the attachment of the only endogenous ligand, chemokine CX3CL1 (fractalkine), released in a soluble form (sCX3CL1) from neurons. Gene transcription changes are a consequence of the signal transducer and activator of the transcription protein (STAT), nuclear factor kappa-light-chain-enhancer of activated B cells (NF-κB) and cAMP/Ca²⁺ response element binding protein (CREB) activation, while inhibiting the members of the class O of forkhead box transcription factors (FOXO). To keep the figure clear, the interaction of CX3CR1 with other receptors has been omitted.

The sCX3CL1 molecule is created by cutting off (marked with scissors) extracellular structures (N-terminal chemokine domain and mucin-like stalk) from the membrane form of fractalkine (mCX3CL1) after the action of a disintegrin and metalloproteinase domain-containing protein 10 (ADAM10), tumor necrosis factor alpha (TNF-α) converting enzyme (TACE or ADAM17), matrix metalloproteinase-2 (MMP-2) or cathepsins (CTS). Neuronal sCX3CL1 stimulates transmembrane metabotropic CX3CR1 on microglial cells, causing conformational changes with subsequent G protein activation. During the nucleotide exchange of the guanosine-5'-triphosphate (GDP) for the guanosine-5'-diphosphate (GTP), the activated alpha subunit (Gαi) dissociates from the G protein Gαβγ heterotrimer. Changes in gene transcription after CX3CR1 activation are accompanied by the release of intracellularly stored calcium ions (Ca²⁺) due to the activation of the phospholipase C (PLC)/inositol-1,4,5-triphosphate (IP3)/protein kinase C (PKC) pathway.

Other abbreviations: Akt – protein kinase B; ERK – extracellular signal-regulated kinase; IκB – inhibitory protein of NF-κB; IKK – IκappaBeta (Iκβ) kinase; JAK – Janus kinase; MEK – mitogen-activated protein kinase kinase; MEKK – MEK kinase; P38 – mitogen-activated protein kinases; PI3K – phosphoinositide 3-kinase; Raf – Raf kinases; Ras – Ras kinases.

3.2. Physiological Action of CX3CL1-CX3CR1 Signaling in Brain Tissue

Under physiological conditions, the CX3CL1-CX3CR1 signaling pathway is involved in various brain functions during development and adulthood. Recently, a key role was attributed to synaptic pruning dependent on microglia, which phagocytize inactive synapses during postnatal maturation

of the brain [77]. CX3CR1^{GFP/GFP} mice, in which microglia synthesize green fluorescent protein (GFP) instead of the CX3CR1 receptor, have more synapses than WT mice, at least until the third week of life [77]. In the hippocampal CA1 region, CX3CR1-deficient (CX3CR1^{-/-}) mice also exhibit reduced numbers of microglia during postnatal development, suggesting that CX3CL1-dependent signaling may exert a chemotactic effect on microglia in the brain [77]. Therefore, genetic ablation of the CX3CR1 receptor may cause microglia to become unresponsive to the chemotactic effects of CX3CL1, thereby reducing the number of microglia in the brain. As a result, a greater density of synapses in CX3CR1^{-/-} mice can be explained by a lower number of microglia.

CX3CL1 also inhibits neuronal migration by increasing neuronal binding to the extracellular matrix [78]. However, CX3CL1 has the opposite effect on microglia. Blocking CX3CR1 inhibits microglial cell migration in response to CX3CL1 [79]. This finding supports the hypothesis that CX3CL1-CX3CR1 signaling may act as a pathway guide for microglia, promoting their colonization of the CNS. Moreover, the migration of microglia into the centers of the developing somatosensory cortex, which usually occurs around postnatal day 5, is delayed by several days in CX3CR1^{-/-}/GFP/GFP mice, even if no differences are detected at postnatal day 9 [80]. The absence of CX3CR1 also delays the maturation of functional glutamate receptors [80]. Microglia affect synapse maturation during individual development, which is generally promoted by the CX3CL1-CX3CR1 signaling pathway. CX3CL1 produced by neurons in the adult brain likely maintains microglia in a quiescent, inactivated state. Microglial activation occurs when CX3CL1 release is reduced, e.g., in the hippocampus of aging rats [64]. Such "homeostatic" effects on microglia may play a significant role in the CX3CL1-CX3CR1 signaling pathway.

Strong activation of microglia in response to intraperitoneal administration of LPS in CX3CR1^{-/-}/GFP/GFP mice has been observed, and apart from that, transplantation of such activated microglia into WT mice produces completely different effects than transplantation of microglia collected from CX3CR1^{+/-} mice [66]. Microglia from CX3CR1^{+/-} mice rapidly migrate from the administration site and mainly infiltrate white matter tracts, whereas microglia from CX3CR1^{-/-} mice remain at the site of administration. Moreover, neuronal loss surrounding activated GFP⁺ microglia collected from CX3CR1^{-/-} mice is more significant and more persistent than that in the brains of WT mice that received microglia collected from CX3CR1^{+/-} mice, probably due to increased IL-1 β release from microglia collected from CX3CR1^{-/-} mice [81]. In a mouse model of Parkinson's disease, CX3CR1^{-/-} mice showed more pronounced cell death in the pars compacta of the substantia nigra than did CX3CR1^{+/+} mice, and similar results were obtained for CX3CL1^{-/-} mice. These findings suggest that the CX3CL1-CX3CR1 signaling pathway modulates the activity of microglia and that disruptions in this pathway may result in their impaired function [81].

In another rat model of Parkinson's disease [82], CX3CL1 was shown to have a neuroprotective effect and prevented neuronal death in the striatum. Indeed, administration of CX3CL1 to the striatum of rats is neuroprotective and causes a significant decrease in activated microglia. Similarly, when glial cells and hippocampal neurons were cocultured in vitro, neuronal death was detected when microglia were previously exposed to LPS, and this effect was partially abrogated by the administration of CX3CL1 [83]. The activation of microglia with LPS changes their phenotype from quiescent to phagocytic and neurotoxic.

4. The role of CX3CL1-CX3CR1 Signaling in CNS Pathology

The CX3CL1-CX3CR1-dependent signaling pathway plays a vital role in autoimmune and inflammatory CNS diseases. Multiple sclerosis is a typical autoimmune CNS disease characterized by inflammation and focal demyelination within the spinal cord and brain [84]. An animal model of experimentally induced autoimmune encephalomyelitis represents a disease closely related to multiple sclerosis [85], in which the expression of CX3CL1 and CX3CR1 changes within the sites of demyelination. Indeed, the accumulation of microglia expressing CX3CR1 receptors has been found in brain damage and inflammation in rats with experimentally induced autoimmune encephalomyelitis without any alterations in the neuronal expression of CX3CL1 [86]. However, an increase in CX3CL1 expression has been found in astrocytes located near regions affected by

inflammation, which may indicate that astrocytes are the source of excessive CX3CL1 release and attract microglia to these regions [86]. Another aspect refers to the increased expression of CX3CL1 in microglia of rats with experimentally induced encephalomyelitis [57]. In this context, the increase in CX3CL1 expression may be a process by which microglia attempt to return to a quiescent phenotype and inhibit their excessive activation.

Moreover, the disease course of CX3CR1^{-/-} mice with experimentally induced encephalomyelitis is more severe than that of WT mice. These mice also show more significant expression of proinflammatory cytokines, such as TNF- α and IL-17, than do WT mice [87]. Conversely, concentrations of the anti-inflammatory cytokine IL-10 are significantly greater in WT mice affected by experimentally induced encephalomyelitis than in CX3CR1^{-/-} mice affected by this disease [87]. These results indicate a close correlation between CX3CL1 and CX3CR1 in the regulation of the autoimmune response. An autoimmune response within the CNS may result in excessive activation of microglia. However, while there is considerable evidence that microglial activation contributes to neuronal damage in multiple sclerosis, there is also evidence that microglia also have essential reparative functions. Microglia can increase the expression of CX3CL1 and CX3CR1, which may constitute a mechanism by which they attempt to prevent hyperactivation and restore the quiescent phenotype in adjacent microglia. Depending on the effectiveness of this autoregulation, microglia may generally acquire a neurotoxic or neuroprotective phenotype. Consistent with this, in the course of multiple sclerosis, one of the polymorphic variants of CX3CR1, namely, CX3CR1^{I249/T280} [88], affects the affinity of CX3CL1 for its receptor and the expression of the receptor itself.

Spinal cord injury significantly damages neurons and completely disrupts axonal continuity, leading to inflammation and neurodegeneration at and around the site of injury [89], which then results in the recruitment of microglia and monocyte-derived macrophages [90]. Microglia and macrophages promote the formation of the glial scar, which reduces the chance of recovering the function of damaged neurons and, thus, the chance of survival of the organism as a whole [91]. CX3CR1^{-/-} mice have a specific subpopulation of macrophages that are not present in WT mice. These macrophages infiltrate the damaged spinal cord and possess unique properties compared to those of macrophages found in WT mice. Microglia in CX3CR1^{-/-} mice produce lower amounts of inducible nitric oxide synthase (iNOS) and IL-6 mRNA after spinal cord injury.

Moreover, in CX3CR1^{-/-} mice, functional recovery after spinal cord injury occurs faster and to a greater extent, suggesting that the relationship between neurons and microglia is in dynamic equilibrium during neuronal regeneration. Therefore, after spinal cord injury, microglia in CX3CR1^{+/+} (WT) mice may release factors that activate astrocytes and promote glial scar formation, inhibiting functional axonal regeneration. Pharmacological blockade of CX3CR1 in an appropriate time window after spinal cord injury may serve as a novel method to inhibit microglial activation and promote neural regeneration. Despite the undoubtedly neuroprotective functions of the CX3CL1-CX3CR1 signaling pathway in the CNS, CX3CL1 may do more harm than good under certain circumstances. Studies conducted in CX3CL1^{-/-} mice to investigate the role of CX3CL1 immediately after ischemic injury suggest that CX3CL1 expression inhibits recovery from ischemic CNS injury [92]. Similar studies in CX3CL1^{-/-} and CX3CR1^{-/-} mice have shown that in both strains of mice, the volume of infarcted tissue after ischemia is lower, and the administration of exogenous CX3CL1 to WT mice reduces the total volume of tissue affected by ischemic infarction. CX3CL1 administration has no effect on CX3CR1^{-/-} mice.

Furthermore, in an in vitro glucose and oxygen deprivation model that reflects in vivo ischemic conditions, CX3CL1 reduced TNF- α release from CX3CR1^{-/-} microglia. These results may explain why administering exogenous CX3CL1 to CX3CR1^{-/-} mice increases the total volume of infarcted tissues, considering the neuroprotective effects of TNF- α [93]. CX3CL1 did not affect TNF- α release in microglia collected from WT mice. Moreover, in CX3CR1^{-/-} mice, the infarct area after ischemia was smaller than that in the WT and heterozygous mice. Greater IL-1 β expression has been observed in the astrocytes of CX3CR1^{+/+} mice than in those of CX3CR1^{-/-} mice. This finding suggests that, under stressful conditions, such as during an ischemic episode, CX3CR1^{-/-} microglia acquire an astrocyte function-altering phenotype by default [94].

Studies on the sex-specific effects of CX3CL1-CX3CR1 signaling have shown that, within 12 weeks of an ischemic event in WT and CX3CR1^{-/-} mice, female WT mice recover more functions than female CX3CR1^{-/-} mice [95], while no difference has been found in males. This finding suggests that, for unknown reasons, signaling dependent on the activation of the CX3CR1 receptor has a more significant neuroprotective effect in the event of ischemic episodes in females than in males.

4.1. CX3CL1-CX3CR1 Pathway in Aging Microglia

Increasing amounts of data are emerging regarding the role of CX3CL1/CX3CR1 signaling in the aged brain. A significant amount of data suggest that the expression of CX3CL1 in the brain of young rodents is high and decreases with age, which reduces the number of ramified microglia and promotes the release of neuroinflammation markers [96]. Moreover, in old mice exposed to peripheral LPS, the microglial response is enhanced [64,96,97], which may confirm the anti-inflammatory and neuroprotective effects of CX3CL1 in young mice. Interestingly, LPS exposure also reduces CX3CR1 expression in old brains more than in young brains, resulting in a long-term decrease in the expression of these receptors on microglia [98]. Recent studies have confirmed these results and have shown that, while the expression of CX3CR1 on microglia returns to normal within 24 hours of exposure to LPS in young mice, this does not occur in old mice [97]. This failure to return regular CX3CR1 expression is accompanied by increased IL-1 β release, often exacerbating existing CNS diseases. Taken together, reduced expression of CX3CL1, CX3CR1, or both proteins in aged brains significantly alters the effectiveness of the signaling axis dependent on these proteins, resulting in both morphological and functional alterations in microglial cell phenotypes, as well as impairment of microglial function. It is known that neurogenesis in the hippocampus decreases during aging. Pharmacological blockade or genetic ablation of CX3CR1 [70,96] has a similar effect on the dentate gyrus of the mouse hippocampus, with a subsequent IL-1 β -dependent decrease in the survival and proliferation rate of neuronal stem cells [96]. In this context, attenuation of CX3CL1-dependent signaling may contribute to excessive activation of microglia [96]. It remains to be determined whether the same phenomenon occurs in humans. Considering the reduced neurogenesis in the hippocampus during cognitive impairment and aging, further studies are recommended to determine the involvement of the CX3CL1/CX3CR1 signaling pathway in the pathologies mentioned above in humans. Activation of the CX3CR1 receptor in microglia regulates PI3K activity, reducing IL-1 β production [99]. Since aging is characterized by a chronic increase in IL-1 β levels in the hippocampus [100] and IL-1 β inhibits the cell cycle in neuronal progenitor cells [101], impaired activation of CX3CR1 receptor-dependent signaling may contribute to the reduced rate of neurogenesis in aged brains, especially because blockade of IL-1 β abrogates these effects [96].

Recent studies have also clarified the role of IL-1 β . Sirtuin 1 (SIRT1), a nicotinamide adenine dinucleotide (NAD⁺)-dependent protein deacetylase, has been associated with neuroprotective effects, which are partially dependent on the inactivation of the p65 subunit of NF- κ B by SIRT1 and, therefore, on the inhibition of the expression of IL-1 β , a protein upregulated by NF- κ B [102]. However, the activated CX3CR1 receptor can inhibit the activity of protein kinase A (PKA); thus, deletion of this receptor may facilitate the activation of PKA and, therefore, the activation of NF- κ B, which is also dependent on this kinase [103]. In CX3CR1^{-/-} microglia, SIRT1 activity increases, which likely helps to prevent excessive activation of NF- κ B, but in old brains, it is insufficient to prevent excessive expression of genes promoted by NF- κ B, including the IL-1 β -encoding gene [104,105].

Previous studies on various animal models of neurodegeneration have shown that the loss of neuronal interactions with microglia caused by damage to the CX3CL1-CX3CR1 signaling pathway results in more significant neurotoxic activity of microglia and, therefore, in a more severe course of neurodegenerative diseases [81]. However, it is unknown whether impaired functioning of the CX3CL1-CX3CR1 signaling pathway occurs as a result or as a cause of increased activation of microglia, while both scenarios may occur during brain aging or diabetic encephalopathy. No differences in CX3CL1 mRNA expression were detected in hippocampal neurons collected from old rats compared with those collected from young rats, which indicates that posttranslational mechanisms are responsible for the decreased CX3CL1 activity [96]. Administration of exogenous

CX3CL1 restores physiological levels of neurogenesis. Moreover, a slight decrease in CX3CL1 expression was observed in middle-aged rats. However, they do not have such an inhibitory effect on the function of the CX3CL1-CX3CR1-dependent signaling axis, as observed in old rats, proving the direct role of aging in the significant inhibition of CX3CL1 expression. In other words, the apparent physiological decline in CX3CL1 expression that occurs during aging may be compensated for during the early but not late stage of this process.

When looking at the interindividual genetic variation in the CX3CR1 coding regions, two single nucleotide polymorphisms (SNPs) can be detected. Interestingly, these polymorphisms are associated with an increased risk of age-related macular degeneration (AMD) [106,107] and a reduced risk of atherosclerosis [108]. Moreover, plasma soluble CX3CR1 levels are significantly greater in people with mild to moderate Alzheimer's disease than in people with severe disease. If we assume that the severity of Alzheimer's disease progresses with age, such observations are consistent with the hypothesis that CX3CL1-CX3CR1 signaling plays a neuroprotective role [109]. Notably, in old mice, voluntary physical exercise increases the CX3CL1 concentration in the brain and, therefore, neurogenesis in the hippocampus [110], which leads to improved hippocampal function [111,112]. Combined, this suggests that decreased physical activity with age may contribute to a decrease in CX3CL1 levels in the brain.

4.2. Common Denominators of Brain Aging, Alzheimer's Disease and Diabetic Encephalopathy

In the course of both Alzheimer's disease and untreated diabetes, microglia may be excessively activated by factors such as oxidative stress and neuroinflammation. In Alzheimer's disease, microglia may be directly activated by extracellular deposits of A β aggregates, while in diabetic encephalopathy, they can be activated by AGEs. Furthermore, damage to the blood-brain barrier occurring in the course of diabetes makes it permeable to substances not generally found in the brain, which may promote neuroinflammation. The pattern of microglial cell activation depends on microglial interactions with neurons, while CX3CL1-CX3CR1 signaling plays a significant role in these interactions. Many studies have indicated that CX3CL1-CX3CR1 signaling may exert a neuroprotective effect by preventing the hyperactivation of microglia and thus the neuroinflammatory response [64,73–75]. However, other studies have suggested that CX3CL1-CX3CR1 activation can be harmful in slightly different contexts [92,93,113]. Therefore, the modulation of CX3CL1-CX3CR1 signaling may have different effects depending on the metabolic context [114]. However, much evidence indicates that, in the course of diabetic encephalopathy, activation of this pathway can exert a neuroprotective effect since it takes part in the inhibition of microglial hyperactivation by neurons, which can prevent neuroinflammation, thus lowering the risk of dementia as a long-term complication of diabetes.

4.3. Neuroinflammation and Neurodegeneration in Diabetic Encephalopathy

The symptoms of DE consist mainly of cognitive deficits resulting from neuroinflammation and neurodegeneration. One of the possible mechanisms underlying these complications of diabetes is persistent inflammation resulting from the pronounced secretion of proinflammatory mediators and pro-oxidant substances [115]. Proinflammatory mediators are predominantly released from glia, including microglia, astrocytes, and oligodendroglia, in the brain [116,117]. The most common microglia-related function is immune surveillance—both in the healthy brain and in the brain affected by various diseases. Microglia constantly explore their microenvironment by extending and retracting their highly motile processes [118,119]. This property is essential for achieving a rapid response to infections or injuries that lead to the activation of microglia, changing their phenotype from quiescent to activated. At the same time, however, chronic excessive activation of microglia in the course of diabetes, e.g., due to hyperglycemia, may adversely affect the brain, leading to chronic neuroinflammation. Activation of microglia may occur in response to disruption of neuronal function, e.g., by excess glycation end products or reactive oxygen species (ROS), and is associated with immunoreactive, morphological, proliferative and migratory changes in microglial phenotypes [118,120]. The activation of microglia allows the elimination of pathogens and debris from other cells

during acute inflammatory reactions, which is a beneficial phenomenon. However, the same activation may have an unfavorable effect on chronic inflammatory reactions, contributing to neurodegeneration [121]. Chronic inflammation within the CNS may result in excessive activation of microglia, which, under such conditions, may excessively release proinflammatory cytokines and undergo oxidative and nitrosative stress [122]. Activated microglia can proliferate and migrate to sites of brain tissue damage, where they undergo morphological changes and alterations in gene expression resulting from interactions among various signaling pathways [123].

Diabetic Encephalopathy – Focus on Microglia

Much evidence indicates that microglia-dependent inflammation within the CNS plays an important role in the pathogenesis of DE. For example, extracellular nucleotides, particularly adenosine triphosphate (ATP), which act through purinergic metabotropic (e.g., P2Y) and purinergic ionotropic (e.g., P2X) receptors, are critical modulators of microglia–neuron communication [124]. Therefore, microglia may affect the course of DE, among other processes, through interactions with neurons. First, neurons become hyperactive in response to neurotoxic factors, hyperglycemia and hyperlipidemia, after which they release slow-acting microglial activators, such as matrix metalloproteinase-9 (MMP-9), ATP and chemokines, mainly monocyte chemoattractant protein-1 (MCP-1, also known as chemokine CCL2), and CX3CL1 (fractalkine). Second, activation of p38 mitogen-activated protein kinases, a class of MAPKs in microglia, produces mediators such as neurotrophins and substances that regulate synaptic transmission and the intensity of inflammation. Microglial inflammation may also result from blocking the interaction between the immunomodulatory molecule CD200 and its receptor CD200R. The CD200/CD200R signaling pathway is responsible for immunosuppressive mechanisms involving the inhibition of macrophages, induction of regulatory T cells, switching of cytokine profiles from Th1 to Th2, inhibition of tumor-specific T-cell immunity and induction of myeloid-derived suppressor cells (MDSCs) [125]. The inflammatory response in microglia also occurs due to the activation of signaling pathways related to pattern recognition receptors (PRRs), such as Toll-like receptors (TLRs), a microglial receptor-adaptor complex known as triggering receptor expressed on myeloid cells 2 (TREM2) and DNAX-activating protein of 12 kDa (DAP12), as well as AGE-RAGE signaling [126–130]. Despite having transporters for the three main energy substrates (glucose, fatty acids, and glutamine), during an acute inflammatory response, microglia may experience an energy deficit because microglial energy consumption is dependent on their degree of activity [130]. Because neuronal hyperactivity caused by neurotoxic factors has a feedback-activating effect on microglia, including through the production of CX3CL1, the microglia–neuron interaction in the DE is a vicious cycle (Figure 3).




Figure 3. The importance of microglia and CX3CL1/CX3CR1 signaling in the vicious cycle of microglia-neuron interaction during neuroinflammation in diabetic encephalopathy.

Microglia activation in diabetic encephalopathy occurs as a result of the action of signaling pathways related to: ❶ pattern recognition receptors (PRRs), including toll-like receptors (TLRs), triggering receptor expressed on myeloid cells 2/DNAX-activating protein of 12 kDa (TRM2/DAP12) and advanced glycation end products/receptor for advanced glycation end-products (AGE-RAGE), ❷ activation of p38 mitogen-activated protein kinases, a class of mitogen-activated protein kinases (MAPKs) p38 MAPK and ❸ purinergic signaling. Microglial inflammation may also develop as a consequence of blocking the interaction of the immunomodulatory protein CD200 with its receptor CD200R (marked with crossed out red lines) ❹, because the CD200/CD200R signaling provides immunosuppression due to the inhibition of macrophages, induction of regulatory T cells, switching of cytokine profiles from T helper-1 (Th1) to T helper-2 (Th2), inhibition of tumor-specific T cell immunity and induction of myeloid-derived suppressor cells (MDSC) [125]. Neuronal hyperactivity in diabetic encephalopathy may be caused by both neurotoxic factors outside microglia and an inflammatory response within microglia. Neurotoxic agents increase the risk of cognitive deficits due to impaired synaptic plasticity. Whatever the cause, neuronal hyperactivity has a feedback activating effect on microglia by releasing slow-acting microglial activators, such as matrix metalloproteinase-9 (MMP-9), adenosine triphosphate (ATP), monocyte chemoattractant protein-1 (MCP-1) and fractalkine (CX3CL1) ❺. The soluble form of CX3CL1 (sCX3CL1) has a pro-inflammatory effect by stimulating metabotropic CX3CR1 receptors expressed in microglial cells ❻.

Therefore, regulating the activity of some signaling pathways within microglia by inhibiting the activation of receptors for ATP (e.g., the purinergic ionotropic receptors P2X4 and P2X7), MMP-9, chemokines (CX3CL1 and CCL2), p38 mitogen-activated protein kinases—a class of mitogen-activated protein kinases (MAPKs), interleukins (IL-1 β , IL-6) and tumor necrosis factor alpha (TNF- α) may contribute to the development of novel treatments for DE [130,131].

5. Concluding Remarks

DE is a common long-term and chronic complication of DM. Therefore, with the high and constantly increasing incidence of diabetes, DE contributes significantly to cognitive impairment and motor dysfunctions. A constant component of the DE pathomechanism is neuroinflammation, which is caused by a complete lack of insulin (e.g., in type 1 diabetes [T1D]) or ineffective action of insulin due to insulin resistance (e.g., in type 2 diabetes [T2D], which most often co-occurs with obesity). In addition to the lack of homeostatic glucose and the anti-inflammatory effects of insulin, which limit NF- κ B activation and subsequent proinflammatory cytokine expression, chronic hyperglycemia also contributes to neurodegenerative processes mainly through its pro-oxidative effects, which damage blood–brain barrier integrity and increase neuronal loss. The observed clinical diversity of DE forms can be explained by the fact that aging is the primary factor for most neurodegenerative diseases and that in many cases, the pathomechanisms of several neurodegenerative diseases overlap (e.g., Alzheimer's disease and Parkinson's disease).

Fractalkine is an intriguing chemokine with the unique properties of an adhesion molecule (mCX3CL1) and chemoattractant (sCX3CL1) that plays a central role in the nervous system. While neurons constitutively express CX3CL1 in the CNS and, it can be induced by TNF- α and IFN- γ in astrocytes, CX3CR1 expression in the brain is limited to microglia. This finding highlights the direction of action of the CX3CL1-CX3CR1 signaling axis, which regulates the level of microglial activity in response to brain injury or inflammation. However, knowledge about the role of CX3CL1 in DE, as well as in other neurodegenerative diseases, remains surprisingly incomplete and controversial. Depending on the clinical context, CX3CL1 may have neuroprotective effects by inhibiting the inflammatory process in microglia or, conversely, maintaining/intensifying inflammation and neurotoxicity. The impact of comorbidities, including CNS aging, should be considered because, as mentioned above, DE does not occur in an isolated form. Therapeutic actions in DE aimed at limiting neuronal hyperactivity, causing impaired synaptic plasticity, should focus

on interrupting the vicious cycle within the microglia–neuron interaction involving the CX3CL1–CX3CR1 signaling pathway. This can be achieved both by restoring neural homeostasis and by limiting the inflammatory response of microglia.

Funding: This research received no external funding.

Institutional Review Board Statement: Not applicable.

Informed Consent Statement: Not applicable.

Data Availability Statement: No new data were created. Instead, the data are quoted from the available cited literature.

Conflicts of Interest: The authors declare no conflict of interest.

Abbreviations

A2AR – adenosine A2A receptor, a G protein-coupled receptor that binds adenosine

ADAM10 – a disintegrin and metalloproteinase domain-containing protein 10

AGEs – advanced glycation end products

Akt – protein kinase B

AMD – age-related macular degeneration

AMPA receptor – α -amino-3-hydroxy-5-methyl-4-isoxazolepropionic acid receptor

ATP – adenosine triphosphate

BV-2 – immortalized murine microglial cell line

CCL2 – chemokine, also known as monocyte chemoattractant protein-1 (MCP-1)

CD40 – cluster of differentiation 40 also known as – tumor necrosis factor receptor superfamily member 5 (TNFRSF5)

CNS – central nervous system

CREB – cyclic adenosine monophosphate(cAMP)/Ca²⁺ response element binding protein

CTS – cathepsins

CX3CL1 – C-X3-C motif chemokine ligand 1, also known as fractalkine or neurotactin

CX3CR1 – high-affinity fractalkine (FKN) receptor or chemokine (C-X3-C motif) ligand 1 (CX3CL1) receptor, also known as G protein-coupled receptor 13 (GPR13), previously known as V28

DAP12 – DNAX-activating protein of 12 kDa

DE – diabetic encephalopathy

DM – diabetes mellitus

ERK1/2 – extracellular signal-regulated kinase 1/2

FOXO – member of the class O of forkhead box transcription factors

G α , G β , G γ – subunits of the heterotrimeric G proteins (G protein complex)

G α i – activated G α subunit of the G protein complex

GABA – γ -aminobutyric acid

GDP – guanosine-5'-diphosphate

GFP – green fluorescent protein

GPR domain – G protein regulatory domain-containing specific protein

GTP – guanosine-5'-triphosphate

IFN- γ – interferon gamma

IKK – IkappaBeta (I κ β) kinase

IL-1 β , IL-6, IL-10, IL-17 – interleukin-1 beta, -6, -10 and -17, respectively

iNOS – inducible nitric oxide synthase

JNK – cJun NH(2)-terminal kinase
 LPS – lipopolysaccharide
 LTP – long-term potentiation
 MAPK – mitogen-activated protein kinase
 MCP-1 – monocyte chemoattractant protein-1, also known as chemokine CCL2
 mCX3CL1 – membrane form of fractalkine (acts as an adhesion molecule)
 MDSC – myeloid-derived suppressor cells
 MEK – mitogen-activated protein kinase kinase
 MEKK – mitogen-activated protein kinase kinase (MEK) kinase
 MHC2 – major histocompatibility complex class II
 MMP-2, MMP-9 – matrix metalloproteinase-2 and -9, respectively
 NAD⁺ – a nicotinamide adenine dinucleotide (NAD⁺)-dependent protein deacetylase
 (an oxidized form)
 NF-κB – nuclear factor kappa-light-chain-enhancer of activated B cells
 NMDA receptor – N-methyl-D-aspartate receptor
 NO – nitric oxide
 P2X, P2X4, P2X7 – purinergic ionotropic receptors
 P2Y – purinergic metabotropic receptor
 P38 – mitogen-activated protein kinases, also known as P38 MAPK
 PI3K – phosphoinositide 3-kinase
 PKA – protein kinase A
 PKC – protein kinase C
 PLC – phospholipase C
 PRRs – pattern recognition receptors
 Raf – Raf kinases
 RAGE – receptors for advanced glycation end-products
 Ras – Ras kinases
 RIC8 – a non-receptor guanine-nucleotide exchange factor for Gα subunits, also known as synebrin
 ROS – reactive oxygen species
 sCX3CL1 – soluble form of fractalkine (acts as a chemoattractant)
 SIRT1 – sirtuin 1, a nicotinamide adenine dinucleotide (NAD⁺)-dependent protein deacetylase
 SNPs – single nucleotide polymorphisms
 STAT – signal transducer and activator of transcription protein
 T1D, T2D – diabetes type 1 and diabetes type 2, respectively
 TACE – tumor necrosis factor alpha (TNF-α) converting enzyme, also called ADAM17
 Th1, Th2 – CD4⁺ T helper-1 and T helper-2 cells, respectively
 TLR4 – toll-like receptor 4
 TLRs – toll-like receptors
 TNF-α – tumor necrosis factor alpha
 TREM2 – triggering receptor expressed on myeloid cells 2
 WT mice – wild-type mice

References

1. Kumar S, Senapati S, Bhattacharya N, Bhattacharya A, Maurya SK, Husain H, Bhatti JS, Pandey AK. Mechanism and recent updates on insulin-related disorders. *World J Clin Cases*. 2023;11(25):5840-5856. doi: 10.12998/wjcc.v11.i25.5840

2. Kibirige D, Chamba N, Andia-Biraro I, Kilonzo K, Laizer SN, Sekitoleko I, Kyazze AP, Ninsiima S, Ssekamatte P, Bongomin F, Mrema LE, Olomi W, Mbunda TD, Ntinginya NE, Sabi I, Sharples K, Hill P, Te Brake L, VandeMaat J, vanCrevel R, Critchley JA; PROTID consortium. Indicators of optimal diabetes care and burden of diabetes complications in Africa: a systematic review and meta-analysis. *BMJ Open*. 2022;12(11):e060786. doi: 10.1136/bmjopen-2022-060786
3. Harding JL, Pavkov ME, Magliano DJ, Shaw JE, Gregg EW. Global trends in diabetes complications: a review of current evidence. *Diabetologia*. 2019;62(1):3-16. doi: 10.1007/s00125-018-4711-2
4. Belenichev I, Aliyeva O, Popazova O, Bukhtiyarova N. Molecular and biochemical mechanisms of diabetic encephalopathy. *Acta Biochim Pol*. 2023;70(4):751-760. doi: 10.18388/abp.2020_6953
5. Strand N, Anderson MA, Attanti S, Gill B, Wie C, Dawodu A, Pagan-Rosado R, Harbell MW, Maloney JA. Diabetic Neuropathy: Pathophysiology Review. *Curr Pain Headache Rep*. 2024. doi: 10.1007/s11916-024-01243-5
6. Oh DJ, Jung JJ, Shin SA, Kim H, Park S, Sohn BK, Koo BK, Moon MK, Kim YK, Lee JY. Brain Structural Alterations, Diabetes Biomarkers, and Cognitive Performance in Older Adults With Dysglycemia. *Front Neurol*. 2021;12:766216. doi: 10.3389/fneur.2021.766216
7. Misra S, Ke C, Srinivasan S, Goyal A, Nyriyenda MJ, Florez JC, Khunti K, Magliano DJ, Luk A. Current insights and emerging trends in early-onset type 2 diabetes. *Lancet Diabetes Endocrinol*. 2023;11(10):768-782. doi: 10.1016/S2213-8587(23)00225-5
8. Cheng X, Tan Y, Li H, Zhang Z, Hui S, Zhang Z, Peng W. Mechanistic Insights and Potential Therapeutic Implications of NRF2 in Diabetic Encephalopathy. *Mol Neurobiol*. 2024. doi: 10.1007/s12035-024-04097-5
9. Dash UK, Mazumdar D, Singh S. High Mobility Group Box Protein (HMGB1): A Potential Therapeutic Target for Diabetic Encephalopathy. *Mol Neurobiol*. 2024. doi: 10.1007/s12035-024-04081-z
10. Han X, Huang S, Zhuang Z, Zhang X, Xie M, Lou N, Hua M, Zhuang X, Yu S, Chen S. Phosphatidate phosphatase Lipin1 involves in diabetic encephalopathy pathogenesis via regulating synaptic mitochondrial dynamics. *Redox Biol*. 2024;69:102996. doi: 10.1016/j.redox.2023.102996
11. Heni M, Kullmann S, Preissl H, Fritsche A, Häring HU. Impaired insulin action in the human brain: causes and metabolic consequences. *Nat Rev Endocrinol*. 2015;11(12):701-11. doi: 10.1038/nrendo.2015.173
12. Benedict C, Hallschmid M, Schultes B, Born J, Kern W. Intranasal insulin to improve memory function in humans. *Neuroendocrinology*. 2007;86(2):136-42. doi: 10.1159/000106378
13. Moosavi M, Naghdi N, Choopani S. Intra CA1 insulin microinjection improves memory consolidation and retrieval. *Peptides*. 2007;28(5):1029-34. doi: 10.1016/j.peptides.2007.02.010
14. Craft S, Newcomer J, Kanne S, Dagogo-Jack S, Cryer P, Sheline Y, Luby J, Dagogo-Jack A, Alderson A. Memory improvement following induced hyperinsulinemia in Alzheimer's disease. *Neurobiol Aging*. 1996;17(1):123-30. doi: 10.1016/0197-4580(95)02002-0
15. Grillo CA, Piroli GG, Lawrence RC, Wrihten SA, Green AJ, Wilson SP, Sakai RR, Kelly SJ, Wilson MA, Mott DD, Reagan LP. Hippocampal Insulin Resistance Impairs Spatial Learning and Synaptic Plasticity. *Diabetes*. 2015;64(11):3927-36. doi: 10.2337/db15-0596
16. Hoscheidt SM, Kellawan JM, Berman SE, Rivera-Rivera LA, Krause RA, Oh JM, Beeri MS, Rowley HA, Wieben O, Carlsson CM, Asthana S, Johnson SC, Schrage WG, Bendlin BB. Insulin resistance is associated with lower arterial blood flow and reduced cortical perfusion in cognitively asymptomatic middle-aged adults. *J Cereb Blood Flow Metab*. 2017;37(6):2249-2261. doi: 10.1177/0271678X16663214
17. Mullins RJ, Diehl TC, Chia CW, Kapogiannis D. Insulin Resistance as a Link between Amyloid-Beta and Tau Pathologies in Alzheimer's Disease. *Front Aging Neurosci*. 2017;9:118. doi: 10.3389/fnagi.2017.00118
18. Watson GS, Peskind ER, Asthana S, Purganan K, Wait C, Chapman D, Schwartz MW, Plymate S, Craft S. Insulin increases CSF Abeta42 levels in normal older adults. *Neurology*. 2003;60(12):1899-903. doi: 10.1212/01.wnl.0000065916.25128.25
19. Yamamoto N, Matsubara T, Sobue K, Tanida M, Kasahara R, Naruse K, Taniura H, Sato T, Suzuki K. Brain insulin resistance accelerates A β fibrillogenesis by inducing GM1 ganglioside clustering in the presynaptic membranes. *J Neurochem*. 2012;121(4):619-28. doi: 10.1111/j.1471-4159.2012.07668.x
20. de la Monte SM. Contributions of brain insulin resistance and deficiency in amyloid-related neurodegeneration in Alzheimer's disease. *Drugs*. 2012;72(1):49-66. doi: 10.2165/11597760-000000000-00000
21. Yoon SO, Park DJ, Ryu JC, Ozer HG, Tep C, Shin YJ, Lim TH, Pastorino L, Kunwar AJ, Walton JC, Nagahara AH, Lu KP, Nelson RJ, Tuszyński MH, Huang K. JNK3 perpetuates metabolic stress induced by A β peptides. *Neuron*. 2012;75(5):824-37. doi: 10.1016/j.neuron.2012.06.024
22. Nan K, Han Y, Fang Q, Huang C, Yu L, Ge W, Xiang F, Tao YX, Cao H, Li J. HMGB1 gene silencing inhibits neuroinflammation via down-regulation of NF- κ B signaling in primary hippocampal neurons induced by A β 25-35. *Int Immunopharmacol*. 2019;67:294-301. doi: 10.1016/j.intimp.2018.12.027
23. Shoelson SE, Herrero L, Naaz A. Obesity, inflammation, and insulin resistance. *Gastroenterology*. 2007;132(6):2169-80. doi: 10.1053/j.gastro.2007.03.059
24. Brownlee M. Biochemistry and molecular cell biology of diabetic complications. *Nature*. 2001;414(6865):813-20. doi: 10.1038/414813a

25. Giacco F, Brownlee M. Oxidative stress and diabetic complications. *Circ Res.* 2010; 107(9):1058-70. doi: 10.1161/CIRCRESAHA.110.223545
26. Byun K, Bayarsaikhan E, Kim D, Son M, Hong J, Jeong GB, Paek SH, Won MH, Lee B. Activated microglial cells synthesize and secrete AGE-albumin. *Anat Cell Biol.* 2012;45(1):47-52. doi: 10.5115/acb.2012.45.1.47
27. Guerin-Dubourg A, Catan A, Bourdon E, Rondeau P. Structural modifications of human albumin in diabetes. *Diabetes Metab.* 2012;38(2):171-8. doi: 10.1016/j.diabet.2011.11.002
28. Olasehinde TA, Oyeleye SI, Olaniran AO, Islam MS. Neuroinflammatory biomarkers in diabetic encephalopathy: Linking cholinergic and cognitive dysfunction. In *Biomarkers in diabetes*; Patel VB, Preedy VR, Eds; Springer: Cham, Switzerland, 2022; pp. 1–20. https://doi.org/10.1007/978-3-030-81303-1_66-1
29. Falvo E, Giatti S, Diviccaro S, Cioffi L, Herian M, Brivio P, Calabrese F, Caruso D, Melcangi RC. Diabetic Encephalopathy in a Preclinical Experimental Model of Type 1 Diabetes Mellitus: Observations in Adult Female Rat. *Int J Mol Sci.* 2023;24(2):1196. doi: 10.3390/ijms24021196
30. Cipolla MJ, Huang Q, Sweet JG. Inhibition of protein kinase C β reverses increased blood-brain barrier permeability during hyperglycemic stroke and prevents edema formation in vivo. *Stroke.* 2011;42(11):3252-7. doi: 10.1161/STROKEAHA.111.623991
31. Jeong JH, Lee DH, Song J. HMGB1 signaling pathway in diabetes-related dementia: Blood-brain barrier breakdown, brain insulin resistance, and A β accumulation. *Biomed Pharmacother.* 2022;150:112933. doi: 10.1016/j.biopha.2022.112933
32. Weller RO, Subash M, Preston SD, Mazanti I, Carare RO. Perivascular drainage of amyloid-beta peptides from the brain and its failure in cerebral amyloid angiopathy and Alzheimer's disease. *Brain Pathol.* 2008;18(2):253-66. doi: 10.1111/j.1750-3639.2008.00133.x
33. Tahara K, Kim HD, Jin JJ, Maxwell JA, Li L, Fukuchi K. Role of toll-like receptor signalling in Abeta uptake and clearance. *Brain.* 2006;129(Pt 11):3006-19. doi: 10.1093/brain/awl249
34. Fujita K, Motoki K, Tagawa K, Chen X, Hama H, Nakajima K, Homma H, Tamura T, Watanabe H, Katsuno M, Matsumi C, Kajikawa M, Saito T, Saido T, Sobue G, Miyawaki A, Okazawa H. HMGB1, a pathogenic molecule that induces neurite degeneration via TLR4-MARCKS, is a potential therapeutic target for Alzheimer's disease. *Sci Rep.* 2016;6:31895. doi: 10.1038/srep31895
35. Takata K, Takada T, Ito A, Asai M, Tawa M, Saito Y, Ashihara E, Tomimoto H, Kitamura Y, Shimohama S. Microglial Amyloid- β 1-40 Phagocytosis Dysfunction Is Caused by High-Mobility Group Box Protein-1: Implications for the Pathological Progression of Alzheimer's Disease. *Int J Alzheimers Dis.* 2012;2012:685739. doi: 10.1155/2012/685739
36. Takata K, Kitamura Y, Tsuchiya D, Kawasaki T, Taniguchi T, Shimohama S. High mobility group box protein-1 inhibits microglial Abeta clearance and enhances Abeta neurotoxicity. *J Neurosci Res.* 2004;78(6):880-91. doi: 10.1002/jnr.20340
37. Wątroba M, Grabowska AD, Szukiewicz D. Effects of Diabetes Mellitus-Related Dysglycemia on the Functions of Blood-Brain Barrier and the Risk of Dementia. *Int J Mol Sci.* 2023;24(12):10069. doi: 10.3390/ijms241210069
38. Pop-Busui R, Boulton AJ, Feldman EL, Bril V, Freeman R, Malik RA, Sosenko JM, Ziegler D. Diabetic Neuropathy: A Position Statement by the American Diabetes Association. *Diabetes Care.* 2017;40(1):136-154. doi: 10.2337/dc16-2042
39. Guastella V, Mick G. Strategies for the diagnosis and treatment of neuropathic pain secondary to diabetic peripheral sensory polyneuropathy. *Diabetes Metab.* 2009;35(1):12-9. doi: 10.1016/j.diabet.2008.09.003
40. Schemmel KE, Padiyara RS, D'Souza JJ. Aldose reductase inhibitors in the treatment of diabetic peripheral neuropathy: a review. *J Diabetes Complications.* 2010;24(5):354-60. doi: 10.1016/j.jdiacomp.2009.07.005
41. Rostène W, Kitabgi P, Parsadaniantz SM. Chemokines: a new class of neuromodulator? *Nat Rev Neurosci.* 2007;8(11):895-903. doi: 10.1038/nrn2255
42. Bazan JF, Bacon KB, Hardiman G, Wang W, Soo K, Rossi D, Greaves DR, Zlotnik A, Schall TJ. A new class of membrane-bound chemokine with a CX3C motif. *Nature.* 1997;385 (6617):640-4. doi: 10.1038/385640a0
43. Pan Y, Lloyd C, Zhou H, Dolich S, Deeds J, Gonzalo JA, Vath J, Gosselin M, Ma J, Dussault B, Woolf E, Alperin G, Culpepper J, Gutierrez-Ramos JC, Gearing D. Neurotactin, a membrane-anchored chemokine upregulated in brain inflammation. *Nature.* 1997;387(6633): 611-7. doi: 10.1038/42491. Erratum in: *Nature* 1997 Sep 4;389(6646):100
44. Chapman GA, Moores K, Harrison D, Campbell CA, Stewart BR, Strijbos PJ. Fractalkine cleavage from neuronal membranes represents an acute event in the inflammatory response to excitotoxic brain damage. *J Neurosci.* 2000;20(15):RC87. doi: 10.1523/JNEUROSCI.20-15-j0004.2000
45. Haskell CA, Cleary MD, Charo IF. Molecular uncoupling of fractalkine-mediated cell adhesion and signal transduction. Rapid flow arrest of CX3CR1-expressing cells is independent of G-protein activation. *J Biol Chem.* 1999;274(15):10053-8. doi: 10.1074/jbc.274.15.10053
46. Hermand P, Pincet F, Carvalho S, Ansanay H, Trinquet E, Daoudi M, Combadière C, Deterre P. Functional adhesiveness of the CX3CL1 chemokine requires its aggregation. Role of the transmembrane domain. *J Biol Chem.* 2008;283(44):30225-34. doi: 10.1074/jbc.M802638200

47. Szukiewicz D. CX3CL1 (Fractalkine)-CX3CR1 Axis in Inflammation-Induced Angiogenesis and Tumorigenesis. *International Journal of Molecular Sciences*. 2024; 25(9):4679. <https://doi.org/10.3390/ijms25094679>
48. Harrison JK, Jiang Y, Chen S, Xia Y, Maciejewski D, McNamara RK, Streit WJ, Salafranca MN, Adhikari S, Thompson DA, Botti P, Bacon KB, Feng L. Role for neuronally derived fractalkine in mediating interactions between neurons and CX3CR1-expressing microglia. *Proc Natl Acad Sci U S A*. 1998;95(18):10896-901. doi: 10.1073/pnas.95.18.10896
49. Yoshida H, Imaizumi T, Fujimoto K, Matsuo N, Kimura K, Cui X, Matsumiya T, Tanji K, Shibata T, Tamo W, Kumagai M, Satoh K. Synergistic stimulation, by tumor necrosis factor-alpha and interferon-gamma, of fractalkine expression in human astrocytes. *Neurosci Lett*. 2001;303(2):132-6. doi: 10.1016/s0304-3940(01)01699-8
50. Lyons A, Lynch AM, Downer EJ, Hanley R, O'Sullivan JB, Smith A, Lynch MA. Fractalkine-induced activation of the phosphatidylinositol-3 kinase pathway attenuates microglial activation in vivo and in vitro. *J Neurochem*. 2009;110(5):1547-56. doi: 10.1111/j.1471-4159.2009.06253.x
51. Deiva K, Geeraerts T, Salim H, Leclerc P, Héry C, Hugel B, Freyssinet JM, Tardieu M. Fractalkine reduces N-methyl-D-aspartate-induced calcium flux and apoptosis in human neurons through extracellular signal-regulated kinase activation. *Eur J Neurosci*. 2004;20(12): 3222-32. doi: 10.1111/j.1460-9568.2004.03800.x
52. Meucci O, Fatatis A, Simen AA, Bushell TJ, Gray PW, Miller RJ. Chemokines regulate hippocampal neuronal signaling and gp120 neurotoxicity. *Proc Natl Acad Sci U S A*. 1998;95(24):14500-5. doi: 10.1073/pnas.95.24.14500
53. Meucci O, Fatatis A, Simen AA, Miller RJ. Expression of CX3CR1 chemokine receptors on neurons and their role in neuronal survival. *Proc Natl Acad Sci U S A*. 2000;97(14):8075-80. doi: 10.1073/pnas.090017497. Erratum in: *Proc Natl Acad Sci U S A* 2001 Dec 18;98(26):15393.
54. Limatola C, Lauro C, Catalano M, Ciotti MT, Bertollini C, Di Angelantonio S, Ragozzino D, Eusebi F. Chemokine CX3CL1 protects rat hippocampal neurons against glutamate-mediated excitotoxicity. *J Neuroimmunol*. 2005;166(1-2):19-28. doi: 10.1016/j.jneuroim.2005.03.023
55. Roseti C, Fucile S, Lauro C, Martinello K, Bertollini C, Esposito V, Mascia A, Catalano M, Aronica E, Limatola C, Palma E. Fractalkine/CX3CL1 modulates GABAA currents in human temporal lobe epilepsy. *Epilepsia*. 2013;54(10):1834-44. doi: 10.1111/epi.12354
56. Maggi L, Trettel F, Scianni M, Bertollini C, Eusebi F, Fredholm BB, Limatola C. LTP impairment by fractalkine/CX3CL1 in mouse hippocampus is mediated through the activity of adenosine receptor type 3 (A3R). *J Neuroimmunol*. 2009;215(1-2):36-42. doi: 10.1016/j.jneuroim.2009.07.016
57. Scianni M, Antonilli L, Chece G, Cristalli G, Di Castro MA, Limatola C, Maggi L. Fractalkine (CX3CL1) enhances hippocampal N-methyl-D-aspartate receptor (NMDAR) function via D-serine and adenosine receptor type A2 (A2AR) activity. *J Neuroinflammation*. 2013;10:108. doi: 10.1186/1742-2094-10-108
58. Lauro C, Di Angelantonio S, Cipriani R, Sobrero F, Antonilli L, Brusadin V, Ragozzino D, Limatola C. Activity of adenosine receptors type 1 Is required for CX3CL1-mediated neuroprotection and neuromodulation in hippocampal neurons. *J Immunol*. 2008;180(11):7590-6. doi: 10.4049/jimmunol.180.11.7590
59. Mizuno T, Kawanokuchi J, Numata K, Suzumura A. Production and neuroprotective functions of fractalkine in the central nervous system. *Brain Res*. 2003;979(1-2):65-70. doi: 10.1016/s0006-8993(03)02867-1
60. Biber K, Neumann H, Inoue K, Boddeke HW. Neuronal 'On' and 'Off' signals control microglia. *Trends Neurosci*. 2007;30(11):596-602. doi: 10.1016/j.tins.2007.08.007
61. Ransohoff RM, Perry VH. Microglial physiology: unique stimuli, specialized responses. *Annu Rev Immunol*. 2009;27:119-45. doi: 10.1146/annurev.immunol.021908
62. Mattison HA, Nie H, Gao H, Zhou H, Hong JS, Zhang J. Suppressed pro-inflammatory response of microglia in CX3CR1 knockout mice. *J Neuroimmunol*. 2013;257(1-2):110-5. doi: 10.1016/j.jneuroim.2013.02.008
63. Chen Y, Green SR, Almazan F, Quehenberger O. The amino terminus and the third extracellular loop of CX3CR1 contain determinants critical for distinct receptor functions. *Mol Pharmacol*. 2006;69(3):857-65. doi: 10.1124/mol.105.015909
64. Kharche S, Joshi M, Chattopadhyay A, Sengupta D. Conformational plasticity and dynamic interactions of the N-terminal domain of the chemokine receptor CXCR1. *PLoS Comput Biol*. 2021;17(5):e1008593. doi: 10.1371/journal.pcbi
65. Srivastava D, Gakhar L, Artemyev NO. Structural underpinnings of Ric8A function as a G-protein α -subunit chaperone and guanine-nucleotide exchange factor. *Nat Commun*. 2019;10(1):3084. doi: 10.1038/s41467-019-11088-x
66. Wright SJ, Inchausti R, Eaton CJ, Krystofova S, Borkovich KA. RIC8 is a guanine-nucleotide exchange factor for Galpha subunits that regulates growth and development in *Neurospora crassa*. *Genetics*. 2011;189(1):165-76. doi: 10.1534/genetics.111.129270

67. Weis WI, Kobilka BK. The Molecular Basis of G Protein-Coupled Receptor Activation. *Annu Rev Biochem.* 2018;87:897-919. doi: 10.1146/annurev-biochem-060614-033910
68. Loh SX, Ekinci Y, Spray L, Jeyalan V, Olin T, Richardson G, Austin D, Alkhalil M, Spyridopoulos I. Fractalkine Signalling (CX3CL1/CX3CR1 Axis) as an Emerging Target in Coronary Artery Disease. *J Clin Med.* 2023;12(14):4821. doi: 10.3390/jcm12144821
69. Zhuang Q, Ou J, Zhang S, Ming Y. Crosstalk between the CX3CL1/CX3CR1 Axis and Inflammatory Signaling Pathways in Tissue Injury. *Curr Protein Pept Sci.* 2019;20(8):844-854. doi: 10.2174/1389203720666190305165722
70. Arnoux I, Audinat E. Fractalkine Signaling and Microglia Functions in the Developing Brain. *Neural Plast.* 2015;2015:689404. doi: 10.1155/2015/689404
71. Lee YS, Morinaga H, Kim JJ, Lagakos W, Taylor S, Keshwani M, Perkins G, Dong H, Kayali AG, Sweet IR, Olefsky J. The fractalkine/CX3CR1 system regulates β cell function and insulin secretion. *Cell.* 2013;153(2):413-25. doi: 10.1016/j.cell.2013.03.001
72. Wang A, Yang T, Zhang L, Jia L, Wu Q, Yao S, Xu J, Yang H. IP3-Mediated Calcium Signaling Is Involved in the Mechanism of Fractalkine-Induced Hyperalgesia Response. *Med Sci Monit.* 2018;24:8804-8811. doi: 10.12659/MSM.913787
73. Volin MV, Huynh N, Klosowska K, Reyes RD, Woods JM. Fractalkine-induced endothelial cell migration requires MAP kinase signaling. *Pathobiology.* 2010;77(1):7-16. doi: 10.1159/000272949
74. Wojdasiewicz P, Turczyn P, Dobies-Krzesniak B, Frasunska J, Tarnacka B. Role of CX3CL1/CX3CR1 Signaling Axis Activity in Osteoporosis. *Mediators Inflamm.* 2019;2019:7570452. doi: 10.1155/2019/7570452
75. Park J, Song KH, Ha H. Fractalkine increases mesangial cell proliferation through reactive oxygen species and mitogen-activated protein kinases. *Transplant Proc.* 2012;44(4):1026-8. doi: 10.1016/j.transproceed.2012.03.045
76. Conroy MJ, Lysaght J. CX3CL1 Signaling in the Tumor Microenvironment. *Adv Exp Med Biol.* 2020;1231:1-12. doi: 10.1007/978-3-030-36667-4_1
77. Paolicelli RC, Bolascho G, Pagani F, Maggi L, Scianni M, Panzanelli P, Giustetto M, Ferreira TA, Guiducci E, Dumas L, Ragozzino D, Gross CT. Synaptic pruning by microglia is necessary for normal brain development. *Science.* 2011;333(6048):1456-8. doi: 10.1126/science.1202529
78. Lauro C, Catalano M, Trettel F, Mainiero F, Ciotti MT, Eusebi F, Limatola C. The chemokine CX3CL1 reduces migration and increases adhesion of neurons with mechanisms dependent on the beta1 integrin subunit. *J Immunol.* 2006;177(11):7599-606. doi: 10.4049/jimmunol.177.11.7599
79. Maciejewski-Lenoir D, Chen S, Feng L, Maki R, Bacon KB. Characterization of fractalkine in rat brain cells: migratory and activation signals for CX3CR-1-expressing microglia. *J Immunol.* 1999;163(3):1628-35.
80. Hoshiko M, Arnoux I, Avignone E, Yamamoto N, Audinat E. Deficiency of the microglial receptor CX3CR1 impairs postnatal functional development of thalamocortical synapses in the barrel cortex. *J Neurosci.* 2012;32(43):15106-11. doi: 10.1523/JNEUROSCI.1167-12.2012
81. Cardona AE, Pioro EP, Sasse ME, Kostenko V, Cardona SM, Dijkstra IM, Huang D, Kidd G, Dombrowski S, Dutta R, Lee JC, Cook DN, Jung S, Lira SA, Littman DR, Ransohoff RM. Control of microglial neurotoxicity by the fractalkine receptor. *Nat Neurosci.* 2006;9(7):917-24. doi: 10.1038/nn1715
82. Pabon MM, Bachstetter AD, Hudson CE, Gemma C, Bickford PC. CX3CL1 reduces neurotoxicity and microglial activation in a rat model of Parkinson's disease. *J Neuroinflammation.* 2011;8:9. doi: 10.1186/1742-2094-8-9
83. Zujovic V, Benavides J, Vigé X, Carter C, Taupin V. Fractalkine modulates TNF-alpha secretion and neurotoxicity induced by microglial activation. *Glia.* 2000;29(4):305-15.
84. Lassmann H, van Horssen J, Mahad D. Progressive multiple sclerosis: pathology and pathogenesis. *Nat Rev Neurol.* 2012;8(11):647-56. doi: 10.1038/nrneurol.2012.168
85. Constantinescu CS, Farooqi N, O'Brien K, Gran B. Experimental autoimmune encephalomyelitis (EAE) as a model for multiple sclerosis (MS). *Br J Pharmacol.* 2011; 164(4):1079-106. doi: 10.1111/j.1476-5381.2011.01302.x
86. Sunnemark D, Eltayeb S, Nilsson M, Wallström E, Lassmann H, Olsson T, Berg AL, Ericsson-Dahlstrand A. CX3CL1 (fractalkine) and CX3CR1 expression in myelin oligodendrocyte glycoprotein-induced experimental autoimmune encephalomyelitis: kinetics and cellular origin. *J Neuroinflammation.* 2005;2:17. doi: 10.1186/1742-2094-2-17
87. Garcia JA, Pino PA, Mizutani M, Cardona SM, Charo IF, Ransohoff RM, Forsthuber TG, Cardona AE. Regulation of adaptive immunity by the fractalkine receptor during autoimmune inflammation. *J Immunol.* 2013;191(3):1063-72. doi: 10.4049/jimmunol.1300040
88. Stojković L, Djurić T, Stanković A, Dinčić E, Stančić O, Veljković N, Alavantić D, Zivković M. The association of V249I and T280M fractalkine receptor haplotypes with disease course of multiple sclerosis. *J Neuroimmunol.* 2012;245(1-2):87-92. doi: 10.1016/j.jneuroim.2011.12.028
89. Thuret S, Moon LD, Gage FH. Therapeutic interventions after spinal cord injury. *Nat Rev Neurosci.* 2006;7(8):628-43. doi: 10.1038/nrn1955. Erratum in: *Nat Rev Neurosci.* 2006 Nov;7(11):902.

90. Shechter R, London A, Varol C, Raposo C, Cusimano M, Yovel G, Rolls A, Mack M, Pluchino S, Martino G, Jung S, Schwartz M. Infiltrating blood-derived macrophages are vital cells playing an anti-inflammatory role in recovery from spinal cord injury in mice. *PLoS Med.* 2009;6(7):e1000113. doi: 10.1371/journal.pmed.1000113
91. Silver J, Miller JH. Regeneration beyond the glial scar. *Nat Rev Neurosci.* 2004;5(2):146-56. doi: 10.1038/nrn1326
92. Soriano SG, Amaravadi LS, Wang YF, Zhou H, Yu GX, Tonra JR, Fairchild-Huntress V, Fang Q, Dunmore JH, Huszar D, Pan Y. Mice deficient in fractalkine are less susceptible to cerebral ischemia-reperfusion injury. *J Neuroimmunol.* 2002;125(1-2):59-65. doi: 10.1016/s0165-5728(02)00033-4
93. Lambertsen KL, Clausen BH, Babcock AA, Gregersen R, Fenger C, Nielsen HH, Haugaard LS, Wirenfeldt M, Nielsen M, Dagnaes-Hansen F, Bluethmann H, Faergeman NJ, Meldgaard M, Deierborg T, Finsen B. Microglia protect neurons against ischemia by synthesis of tumor necrosis factor. *J Neurosci.* 2009;29(5):1319-30. doi: 10.1523/JNEUROSCI.5505-08.2009
94. Dénes A, Ferenczi S, Halász J, Környei Z, Kovács KJ. Role of CX3CR1 (fractalkine receptor) in brain damage and inflammation induced by focal cerebral ischemia in mouse. *J Cereb Blood Flow Metab.* 2008;28(10):1707-21. doi: 10.1038/jcbfm.2008.64
95. Pimentel-Coelho PM, Michaud JP, Rivest S. Evidence for a gender-specific protective role of innate immune receptors in a model of perinatal brain injury. *J Neurosci.* 2013;33(28):11556-72. doi: 10.1523/JNEUROSCI.0535-13.2013
96. Bachstetter AD, Morganti JM, Jernberg J, Schlunk A, Mitchell SH, Brewster KW, Hudson CE, Cole MJ, Harrison JK, Bickford PC, Gemma C. Fractalkine and CX 3 CR1 regulate hippocampal neurogenesis in adult and aged rats. *Neurobiol Aging.* 2011;32(11):2030-44. doi: 10.1016/j.neurobiolaging.2009.11.022
97. Wynne AM, Henry CJ, Huang Y, Cleland A, Godbout JP. Protracted downregulation of CX3CR1 on microglia of aged mice after lipopolysaccharide challenge. *Brain Behav Immun.* 2010;24(7):1190-201. doi: 10.1016/j.bbi.2010.05.011
98. Norden DM, Godbout JP. Review: microglia of the aged brain: primed to be activated and resistant to regulation. *Neuropathol Appl Neurobiol.* 2013;39(1):19-34. doi: 10.1111/j.1365-2990.2012.01306.x
99. Ré DB, Przedborski S. Fractalkine: moving from chemotaxis to neuroprotection. *Nat Neurosci.* 2006;9(7):859-61. doi: 10.1038/nn0706-859
100. Gemma C, Bickford PC. Interleukin-1beta and caspase-1: players in the regulation of age-related cognitive dysfunction. *Rev Neurosci.* 2007;18(2):137-48. doi: 10.1515/revneuro.2007.18.2.137
101. Koo JW, Duman RS. IL-1beta is an essential mediator of the antineurogenic and anhedonic effects of stress. *Proc Natl Acad Sci U S A.* 2008;105(2):751-6. doi: 10.1073/pnas.0708092105
102. Chen J, Zhou Y, Mueller-Steiner S, Chen LF, Kwon H, Yi S, Mucke L, Gan L. SIRT1 protects against microglia-dependent amyloid-beta toxicity through inhibiting NF-kappaB signaling. *J Biol Chem.* 2005;280(48):40364-74. doi: 10.1074/jbc.M509329200
103. Min KJ, Yang MS, Jou I, Joe EH. Protein kinase A mediates microglial activation induced by plasminogen and gangliosides. *Exp Mol Med.* 2004;36(5):461-7. doi: 10.1038/emmm.2004.58
104. Sellner S, Paricio-Montesinos R, Spieß A, Masuch A, Erny D, Harsan LA, Elverfeldt DV, Schwabenland M, Biber K, Staszewski O, Lira S, Jung S, Prinz M, Blank T. Microglial CX3CR1 promotes adult neurogenesis by inhibiting Sirt 1/p65 signaling independent of CX3CL1. *Acta Neuropathol Commun.* 2016;4(1):102. doi: 10.1186/s40478-016-0374-8
105. Liu TF, Yoza BK, El Gazzar M, Vachharajani VT, McCall CE. NAD⁺-dependent SIRT1 deacetylase participates in epigenetic reprogramming during endotoxin tolerance. *J Biol Chem.* 2011;286(11):9856-64. doi: 10.1074/jbc.M110.196790
106. Combadière C, Feumi C, Raoul W, Keller N, Rodéro M, Pézard A, Lavalette S, Houssier M, Jonet L, Picard E, Debré P, Sirinyan M, Deterre P, Ferroukhi T, Cohen SY, Chauvaud D, Jeanny JC, Chemtob S, Behar-Cohen F, Sennlaub F. CX3CR1-dependent subretinal microglia cell accumulation is associated with cardinal features of age-related macular degeneration. *J Clin Invest.* 2007;117(10):2920-8. doi: 10.1172/JCI31692
107. Tuo J, Smith BC, Bojanowski CM, Meleth AD, Gery I, Csaky KG, Chew EY, Chan CC. The involvement of sequence variation and expression of CX3CR1 in the pathogenesis of age-related macular degeneration. *FASEB J.* 2004;18(11):1297-9. doi: 10.1096/fj.04-1862fj
108. McDermott DH, Fong AM, Yang Q, Sechler JM, Cupples LA, Merrell MN, Wilson PW, D'Agostino RB, O'Donnell CJ, Patel DD, Murphy PM. Chemokine receptor mutant CX3CR1-M280 has impaired adhesive function and correlates with protection from cardiovascular disease in humans. *J Clin Invest.* 2003;111(8):1241-50. doi: 10.1172/JCI16790
109. Kim TS, Lim HK, Lee JY, Kim DJ, Park S, Lee C, Lee CU. Changes in the levels of plasma soluble fractalkine in patients with mild cognitive impairment and Alzheimer's disease. *Neurosci Lett.* 2008;436(2):196-200. doi: 10.1016/j.neulet.2008.03.019

110. Vukovic J, Colditz MJ, Blackmore DG, Ruitenberg MJ, Bartlett PF. Microglia modulate hippocampal neural precursor activity in response to exercise and aging. *J Neurosci.* 2012;32(19):6435-43. doi: 10.1523/JNEUROSCI.5925-11.2012
111. Trinchero MF, Buttner KA, Sulkes Cuevas JN, Temprana SG, Fontanet PA, Monzón-Salinas MC, Ledda F, Paratcha G, Schinder AF. High Plasticity of New Granule Cells in the Aging Hippocampus. *Cell Rep.* 2017;21(5):1129-1139. doi: 10.1016/j.celrep.2017.09.064
112. Maejima H, Kanemura N, Kokubun T, Murata K, Takayanagi K. Exercise enhances cognitive function and neurotrophin expression in the hippocampus accompanied by changes in epigenetic programming in senescence-accelerated mice. *Neurosci Lett.* 2018;665:67-73. doi: 10.1016/j.neulet.2017.11.023
113. Cipriani R, Villa P, Chece G, Lauro C, Paladini A, Micotti E, Perego C, De Simoni MG, Fredholm BB, Eusebi F, Limatola C. CX3CL1 is neuroprotective in permanent focal cerebral ischemia in rodents. *J Neurosci.* 2011;31(45):16327-35. doi: 10.1523/JNEUROSCI.3611-11.2011
114. Mecca C, Giambanco I, Donato R, Arcuri C. Microglia and Aging: The Role of the TREM2-DAP12 and CX3CL1-CX3CR1 Axes. *Int J Mol Sci.* 2018;19(1):318. doi: 10.3390/ijms19010318
115. Pabreja K, Dua K, Sharma S, Padi SS, Kulkarni SK. Minocycline attenuates the development of diabetic neuropathic pain: possible anti-inflammatory and anti-oxidant mechanisms. *Eur J Pharmacol.* 2011;661(1-3):15-21. doi: 10.1016/j.ejphar.2011.04.014
116. Marchand F, Perretti M, McMahon SB. Role of the immune system in chronic pain. *Nat Rev Neurosci.* 2005;6(7):521-32. doi: 10.1038/nrn1700
117. Tsuda M, Inoue K, Salter MW. Neuropathic pain and spinal microglia: a big problem from molecules in "small" glia. *Trends Neurosci.* 2005;28(2):101-7. doi: 10.1016/j.tins.2004.12.002
118. Davalos D, Grutzendler J, Yang G, Kim JV, Zuo Y, Jung S, Littman DR, Dustin ML, Gan WB. ATP mediates rapid microglial response to local brain injury in vivo. *Nat Neurosci.* 2005; 8(6):752-8. doi: 10.1038/nn1472
119. Nimmerjahn A, Kirchhoff F, Helmchen F. Resting microglial cells are highly dynamic surveillants of brain parenchyma in vivo. *Science.* 2005;308(5726):1314-8. doi: 10.1126/science.1110647
120. Tambuyzer BR, Ponsaerts P, Nouwen EJ. Microglia: gatekeepers of central nervous system immunology. *J Leukoc Biol.* 2009;85(3):352-70. doi: 10.1189/jlb.0608385
121. Chan WY, Kohsaka S, Rezaie P. The origin and cell lineage of microglia: new concepts. *Brain Res Rev.* 2007;53(2):344-54. doi: 10.1016/j.brainresrev.2006.11.002
122. Beynon SB, Walker FR. Microglial activation in the injured and healthy brain: what are we really talking about? Practical and theoretical issues associated with the measurement of changes in microglial morphology. *Neuroscience.* 2012;225:162-71. doi: 10.1016/j.neuroscience.2012.07.029
123. David S, Kroner A. Repertoire of microglial and macrophage responses after spinal cord injury. *Nat Rev Neurosci.* 2011;12(7):388-99. doi: 10.1038/nrn3053
124. Rassendren F, Audinat E. Purinergic signaling in epilepsy. *J Neurosci Res.* 2016;94(9):781-93. doi: 10.1002/jnr.23770
125. Kotwica-Mojzycz K, Jodłowska-Jędrych B, Mojzycz M. CD200:CD200R Interactions and Their Importance in Immunoregulation. *Int J Mol Sci.* 2021;22(4):1602. doi: 10.3390/ijms22041602
126. Fiebich BL, Batista CRA, Saliba SW, Yousif NM, de Oliveira ACP. Role of Microglia TLRs in Neurodegeneration. *Front Cell Neurosci.* 2018;12:329. doi: 10.3389/fncel.2018.00329
127. Konishi H, Kiyama H. Non-pathological roles of microglial TREM2/DAP12: TREM2/DAP12 regulates the physiological functions of microglia from development to aging. *Neurochem Int.* 2020;141:104878. doi: 10.1016/j.neuint.2020.104878
128. Kobayashi M, Konishi H, Sayo A, Takai T, Kiyama H. TREM2/DAP12 Signal Elicits Proinflammatory Response in Microglia and Exacerbates Neuropathic Pain. *J Neurosci.* 2016;36(43):11138-11150. doi: 10.1523/JNEUROSCI.1238-16.2016
129. Juranek J, Ray R, Banach M, Rai V. Receptor for advanced glycation end-products in neurodegenerative diseases. *Rev Neurosci.* 2015;26(6):691-8. doi: 10.1515/revneuro-2015-0003
130. Liu Y, Li M, Zhang Z, Ye Y, Zhou J. Role of microglia-neuron interactions in diabetic encephalopathy. *Ageing Res Rev.* 2018;42:28-39. doi: 10.1016/j.arr.2017.12.005
131. Vargas-Soria M, García-Alloza M, Corraliza-Gómez M. Effects of diabetes on microglial physiology: a systematic review of in vitro, preclinical and clinical studies. *J Neuroinflammation.* 2023;20(1):57. doi: 10.1186/s12974-023-02740-x

Disclaimer/Publisher's Note: The statements, opinions and data contained in all publications are solely those of the individual author(s) and contributor(s) and not of MDPI and/or the editor(s). MDPI and/or the editor(s) disclaim responsibility for any injury to people or property resulting from any ideas, methods, instructions or products referred to in the content.